Robust data: The essential foundation of a revised staging system for pleural mesothelioma

Journal of Thoracic Oncology

Volumn 7, Issue 11, 2012, Pages 1623-1624

  Kindler, Hedy Lee ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DECORTICATION; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; METASTASIS; MULTIMODALITY CANCER THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84867898701     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182730e0e     Document Type: Editorial

References (21)

1. Treasure T. Mesothelioma: beneft from surgical resection is questionable. J Thoracic Oncol 2007;2:885-886.
2. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12:1093-1094.
3. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737-743.
4. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic signifcance in the multimodality therapy of diffuse, malignant mesothe-lioma. J Clin Oncol 1993;11:1172-1178.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
6. van Meerbeeck J P, Gaafar R, Manegold C, et al.; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothe-lioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
7. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012;30:2509-2515.
8. Krug LM, Kindler H, Calvert H, et al. VANTAGE 14: Vorinostat in patients with advanced malignant pleural mesothelioma who have failed prior pemetrexed and either cisplatin or carboplatin therapy: A phase III, randomized, double-blind, placebo-controlled trial. Eur J Ca 2011; 47:2
9. Treasure T, Lang-Lazdunski L, Waller D, et al.; MARS trialists. Extrapleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-772.
10. Butchart EG, Ashcroft T, Barnsley WC, Holden M P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24.
11. Mattson K. Natural history and clinical staging of malignant mesothelioma. Eur J Respir Dis 1982; 63 (suppl 124):87
12. Chahinian A P, Kirschner PA, Dikman SH, Rammos KS, Holland JF. Pulmonary metastatic leiomyosarcoma coexisting with pulmonary chon-droma in Carney's triad. Arch Intern Med 1983;143:1462-1464.
13. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 1993;72:394-404.
14. Rusch V W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
15. International Union Against Cancer. TNM Classifcation of Malignant Tumours. 7th ed. Oxford, UK:Wiley-Blackwell;2009.
16. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York:Springer;2010
17. Heelan R. Staging and response to therapy of malignant pleural mesothe-lioma. Lung Cancer 2004;45 Suppl 1:S59-S61.
18. Rusch V W, Asamura H. Response: a critique of the international association for the study of lung cancer lymph node map. J Thorac Oncol 2012;7:481.
19. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifcation of malignant tumours. J Thorac Oncol 2007;2:706-714.
20. Rami-Porta R, Ball D, Crowley J, et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classifcation for lung cancer. J Thorac Oncol 2007;2:593-602.
21. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.